loading
전일 마감가:
$1.42
열려 있는:
$1.44
하루 거래량:
116.41K
Relative Volume:
0.34
시가총액:
$25.27M
수익:
-
순이익/손실:
$-33.08M
주가수익비율:
-0.4456
EPS:
-2.94
순현금흐름:
$-25.68M
1주 성능:
-2.24%
1개월 성능:
+24.76%
6개월 성능:
-8.71%
1년 성능:
+77.03%
1일 변동 폭
Value
$1.31
$1.45
1주일 범위
Value
$1.2309
$1.45
52주 변동 폭
Value
$0.603
$2.55

Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile

Name
명칭
Chemomab Therapeutics Ltd Adr
Name
전화
972-77-331-0156
Name
주소
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Name
직원
16
Name
트위터
Name
다음 수익 날짜
2024-11-14
Name
최신 SEC 제출 서류
Name
CMMB's Discussions on Twitter

CMMB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CMMB
Chemomab Therapeutics Ltd Adr
1.31 25.27M 0 -33.08M -25.68M -2.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.86 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.22 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.38 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
271.56 32.98B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.97 26.89B 3.81B -644.79M -669.77M -6.24

Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-05-13 개시 Maxim Group Buy
2024-05-06 업그레이드 Oppenheimer Perform → Outperform
2023-12-19 재개 ROTH MKM Buy

Chemomab Therapeutics Ltd Adr 주식(CMMB)의 최신 뉴스

pulisher
Apr 28, 2025

Chemomab reports promising PSC treatment data - Investing.com

Apr 28, 2025
pulisher
Mar 27, 2025

The Aurora Cannabis Inc (NASDAQ: ACB) Stock Price: Is It Overvalued? - Stocks Register

Mar 27, 2025
pulisher
Mar 27, 2025

How Stable And Growing Is Globavend Holdings Ltd (NASDAQ: GVH)? - Stocks Register

Mar 27, 2025
pulisher
Mar 27, 2025

Before Buying AYRO Inc (NASDAQ: AYRO) Stock, Read This First - Stocks Register

Mar 27, 2025
pulisher
Mar 27, 2025

Is Advance Auto Parts Inc (NYSE: AAP) A Good Investment For New Investors Now? - stocksregister.com

Mar 27, 2025
pulisher
Mar 27, 2025

Nu Holdings Ltd (NYSE: NU) Has Great Upside Potential - stocksregister.com

Mar 27, 2025
pulisher
Mar 27, 2025

ZEEKR Intelligent Technology Holding Ltd. ADR (NYSE: ZK): Getting A Free Pass? - stocksregister.com

Mar 27, 2025
pulisher
Mar 27, 2025

AT&T, Inc (NYSE: T) Jumps 1.59%: What Could Be On The Way Going Forward? - Stocks Register

Mar 27, 2025
pulisher
Mar 27, 2025

Adma Biologics Inc (NASDAQ: ADMA): Blank Check For Growth? - Stocks Register

Mar 27, 2025
pulisher
Mar 27, 2025

A Bullish 2025 Outlook For Blink Charging Co (NASDAQ: BLNK) Shares - Stocks Register

Mar 27, 2025
pulisher
Mar 27, 2025

In 2025, Linkers Industries Ltd (NASDAQ: LNKS) Shares Will Likely Be Bullish - Stocks Register

Mar 27, 2025
pulisher
Mar 27, 2025

Carrier Global Corp (NYSE: CARR): On Track To A Higher Share Price - Stocks Register

Mar 27, 2025
pulisher
Mar 27, 2025

Before Buying Avantor Inc (NYSE: AVTR) Stock, Read This First - stocksregister.com

Mar 27, 2025
pulisher
Mar 27, 2025

Ally Financial Inc (NYSE: ALLY): An Enticing Stock To Watch - stocksregister.com

Mar 27, 2025
pulisher
Mar 27, 2025

Nebokitug shows promise in PSC treatment trial - Investing.com

Mar 27, 2025
pulisher
Mar 12, 2025

Does DLocal Limited (NASDAQ: DLO) Still Need To Convince Analysts? - stocksregister.com

Mar 12, 2025
pulisher
Mar 10, 2025

Think You Need A Good Stock? Look At This Scilex Holding Company (NASDAQ: SCLX) Analysis - stocksregister.com

Mar 10, 2025
pulisher
Mar 03, 2025

Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - stocksregister.com

Mar 03, 2025
pulisher
Feb 20, 2025

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

How analysts predict Chemomab Therapeutics Ltd ADR (CMMB) will perform this quarter? - US Post News

Feb 19, 2025
pulisher
Feb 19, 2025

Nebokitug positioned as potential first FDA-approved PSC treatment By Investing.com - Investing.com South Africa

Feb 19, 2025
pulisher
Jan 09, 2025

LogicMark Inc (LGMK) Recovers 0.71% From Low: Are We There Yet? - Stocks Register

Jan 09, 2025
pulisher
Nov 19, 2024

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.

Nov 19, 2024
pulisher
Nov 14, 2024

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Investing.com

Nov 14, 2024
pulisher
Feb 14, 2024

symbol__ Stock Quote Price and Forecast - CNN

Feb 14, 2024
pulisher
Jan 13, 2023

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why - Zacks Investment Research

Jan 13, 2023
pulisher
Jun 17, 2021

What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition - Yahoo Finance

Jun 17, 2021
pulisher
Mar 23, 2021

CMMB News Today | Why did Chemomab Therapeutics stock go down today? - MarketBeat

Mar 23, 2021

Chemomab Therapeutics Ltd Adr (CMMB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$72.59
price up icon 0.52%
$21.58
price up icon 0.52%
$32.97
price up icon 0.05%
$27.72
price down icon 0.52%
$101.00
price down icon 3.71%
biotechnology ONC
$255.47
price down icon 0.48%
자본화:     |  볼륨(24시간):